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Increased expression of human leukocyte antigen (HLA) allows tumor cells to be more easily 
detected by the immune system. In previous research, epigenetic modifiers including the histone 
deacetylase inhibitor 3 (HDAC3), RGFP966, has been shown to decrease PD-L1 expression. 
PD-L1 expression inhibits T cell cytotoxicity, and decreasing it can enhance the immune 
response. We hope to elucidate whether or not HLA-ABC expression similarly decreases upon 
exposure to the HDAC3 inhibitor which would be detrimental to immune detection. Two breast 
cancer cell lines that express HLA-ABC are MCF-7 and MDA-MB-231. Our initial results show 
that HLA-ABC is expressed on the MDA-MB-231 and MCF-7 cell lines, while PD-L1 is only 
expressed by MDA-MB-231 cell line as demonstrated by flow cytometry. However, in subsequent 
experiments testing the effect of RGFP966, there were inconsistent results regarding the change 
in expression of HLA-ABC which requires further investigation. In addition, we also wish to 
examine other HLA proteins, such as HLA-E and HLA-G, which have been shown to be 
detrimental to immune detection. Future experiments are planned to optimize the doses of 
RGFP966 to maximize HLA expression in these breast cancer cell lines while limiting the 
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